North Forty Management’s Biogen BIIB Stock Holding History

North Forty Management’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-776	Closed	-$220K	–	8
2016 Q4	$220K	Buy	+776	New	+$230K	0.27%	8

Other funds holding BIIB

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

North Forty Management's BIIB Position: Q1 2017 in Review

North Forty Management sold out of Biogen (BIIB) in Q1 2017, closing a stake of 776 shares — an estimated $220K sold.

North Forty Management first reported a position in BIIB in Q4 2016 and held it in 1 quarter. The position peaked at $220K in Q4 2016. 1,019 funds tracked by Wall St. Rank hold BIIB as of Q1 2017.

North Forty Management reported no remaining Biogen position as of Q1 2017 after selling out during the quarter.
North Forty Management sold 776 Biogen shares in Q1 2017, an estimated $220K.
North Forty Management first reported a position in Biogen in Q4 2016 and held it in 1 quarter.
North Forty Management's Biogen position peaked at $220K in Q4 2016.
1,019 funds tracked by Wall St. Rank held Biogen as of Q1 2017.

Based on North Forty Management's 13F filing for Q1 2017, filed 1 May 2017.